File
| Title | Disorder | Modality | PI/Lead Investigator | Institution |
|---|---|---|---|---|
| Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases | Duchenne Muscular Dystrophy | Monoclonal antibody | Alexis Demonbreun | Northwestern University at Chicago |
| Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding | Spinal cord injury | Peptide | Edward Burgard | Dignify Therapeutics, LLC |
| IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy | Spinal Muscular Atrophy | Antisense oligonucleotide | Steven O'Connor | Shift Pharmaceuticals, LLC |
| Development of Utrophin Site Blocking Oligos (SBOs) to treat Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | Site blocking oligonuclotide | Tejvir S. Khurana | University of Pennsylvania |
| Development of AAV-AIBP for neuroprotecction in glaucoma | Glaucoma | AAV-encoding protein | Wonkyu Ju | University of California- San Diego |
BPN-Biologics Staff
Program Director
Dr. Chris BoshoffHealth Program Specialists
Ms. Shruthi ThomasOperations Coordinator
Ms. Natasha DavisProject ManagersMs. Elena Barnaeva
Dr. Chris Conrad
Dr. Lauren Friedman
Dr. Nagarajan Rangarajan
Dr. Ram Arudchandran